

Supporting Information:

Supplementary Figure Legend:

Supplementary Figure 1: Additional correlates of baseline cytokine/chemokine levels. (A) Association of Log₁₀HCV viral load at baseline with Log₁₀IP-10. (B) Association of Log₁₀MIP-1β with age (years). P-values and adjusted R² were determined by univariable linear regression analysis.

Supplementary Table 1. Correlates of sustained virologic response (SVR) in patients without cirrhosis.

		Relapse	SVR	P-value	OR (95% CI) ^b	
					Unadjusted	Adjusted
BMI	<30	21 (31.8%)	23 (34.8%)	0.18 ^c	1 [Reference]	--
	≥30	6 (9.1%)	16 (24.2%)		2.44 (0.831, 7.86)	
Log ₁₀ IP-10 baseline ^f		2.245 (0.286)	2.42 (0.417)	0.06 ^d	1.15 (1.00, 1.23)	1.28 (1.06, 1.62) [*]
Log ₁₀ IP-10 week 1 ^f		1.905 (0.182)	2.066 (0.386)	0.03 ^e	1.22 (1.01, 1.54)	--
Log ₁₀ MIP1β week 1 ^f		1.119 (0.174)	1.192 (0.253)	0.19 ^d	1.17 (0.93, 1.49)	--
Log ₁₀ IP-10 week 2 ^f		1.871 (0.147)	2.052 (0.401)	0.01 ^e	1.26 (1.04, 1.63)	--
Log ₁₀ MIP1β week 2 ^f		1.112 (0.144)	1.228 (0.253)	0.02 ^e	1.31 (1.02, 1.73)	--
Δ Log ₁₀ MIP1β w0-2		0.198 (0.218)	0.108 (0.245)	0.13	0.84 (0.65, 1.04)	0.72 (0.53, 0.94) [*]

^a Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^b Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^c P-values calculated by Fisher Exact Test

^d P-values calculated by independent sample *t* tests

^e P-values calculated by Wilcoxon rank sum tests

^f Odds ratios were calculated per 0.1 unit increase

BMI, Body Mass Index

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Number and (Percentage) noted for all categorical variables

Supplementary Table 2. Correlates of SVR in patients with genotype 2 HCV infection

		Relapse	SVR	P-value	OR (95% CI) ^a	
					Unadjusted	Adjusted
Age		49.4 (14.3)	54.6 (11.0)	0.16 ^c	1.04 (0.99, 1.09)	--
Sex	F	2 (3.8%)	16 (30.2%)	0.10 ^b	1 [Reference]	--
	M	12 (22.6%)	23 (43.4%)		0.24 (0.03, 1.04)	
Ethnicity	Hispanic	4 (7.5%)	4 (7.5%)	0.19 ^b	1 [Reference]	--
	Not Hispanic	10 (18.9%)	35 (66.0%)		3.5 (0.72, 17.4)	
Treatment Duration (wks)	12	12 (22.6%)	38 (71.7%)	0.17 ^b	1 [Reference]	--
	16	2 (3.77%)	1 (1.89%)		0.16 (0.01, 1.79)	
Log ₁₀ HCV RNA baseline ^e		6.73 (0.67)	6.32 (0.92)	0.14 ^c	0.52 (0.19, 1.15)	0.49 (0.17, 1.14)
Log ₁₀ IP10 week 1 ^d		1.93 (0.30)	2.11 (0.34)	0.08 ^c	1.23 (0.99, 1.63)	--
Log ₁₀ MIP1β week 1 ^d		1.09 (0.22)	1.26 (0.26)	0.02 ^c	1.43 (1.06, 2.08)	1.46 (1.07, 2.15) [*]
Log ₁₀ MIP1β week 2 ^d		1.13 (0.20)	1.27 (0.21)	0.04 ^c	1.40 (1.02, 2.05)	--

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^a Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^b P-values calculated by Fisher Exact Test

^c P-values calculated by independent sample *t* tests

^d Odds ratios were calculated per 0.1 unit increase

^e Odds ratio was calculated per 1 log₁₀ increase in viral load

* p ≤ 0.05; ** p <0.01; *** p <0.001; calculated in final multivariable model

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Number and (Percentage) noted for all categorical variables

Supplementary Table 3. Correlates of SVR in treatment experienced patients

		Relapse	SVR	P-value	OR (95% CI) ^a	
					Unadjusted	Adjusted
Treatment Duration (wks)	12	25 (38.5%)	21 (32.3%)	0.06 ^b	1 [Reference]	1 [Reference]
	16	5 (7.7%)	14 (21.5%)		3.33 (1.08, 11.7)	6.53 (1.52, 36.7) *
Clinical Trial	FUSION	16 (24.6%)	25 (38.5%)	0.20 ^b	1 [Reference]	--
	POSITRON	14 (21.5%)	10 (15.4%)		0.46 (0.16, 1.26)	
Log ₁₀ MCP1 baseline ^d		1.59 (0.17)	1.54 (0.13)	0.19 ^c	0.79 (0.55, 1.11)	0.51 (0.26, 0.88) *
Log ₁₀ MIP1β week 1 ^d		1.13 (0.20)	1.23 (0.19)	0.06 ^c	1.29 (1.00, 1.75)	1.62 (1.06, 2.68) *
Log ₁₀ MIP1β week 2 ^d		1.13 (0.17)	1.20 (0.19)	0.13 ^c	1.25 (0.95, 1.71)	--
Δ Log ₁₀ MIP1β w0-1 ^d		0.14 (0.19)	0.06 (0.21)	0.10 ^c	0.80 (0.60, 1.03)	1.54 (0.88, 2.90)
Δ Log ₁₀ MIP1β w0-2 ^d		0.15 (0.17)	0.09 (0.16)	0.13 ^c	0.79 (0.57, 1.07)	0.67 (0.37, 1.13)
Δ Log ₁₀ MCP1 w0-2 ^d		0.10 (0.13)	0.04 (0.16)	0.14 ^c	0.77 (0.52, 1.09)	--

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^a Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^b P-values calculated by Fisher Exact Test

^c P-values calculated by independent sample *t* tests

^d Odds ratios were calculated per 0.1 unit increase

* p ≤ 0.05; ** p <0.01; *** p <0.001; calculated in final multivariable model

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Supplementary Table 4. Correlates of SVR in treatment naive patients

		Relapse	SVR	P-value	OR (95% CI) ^a	
					Unadjusted	Adjusted
Age		51.2 (9.16)	54.5 (9.33)	0.11 ^c	1.03 (0.98, 1.10)	--
Sex	F	7 (10.6%)	22 (33.3%)	0.13 ^b	1 [Reference]	1 [Reference]
	M	16 (24.2%)	21 (31.8%)		0.42 (0.14, 1.19)	0.40 (0.11, 1.30)
Log ₁₀ IP-10 baseline ^d		2.21 (0.24)	2.46 (0.40)	0.008 ^c	1.29 (1.08, 1.62)	1.37 (1.08, 1.83) *
Log ₁₀ MIP1β baseline ^d		1.28 (0.18)	1.38 (0.21)	0.06 ^c	1.31 (1.00, 1.77)	--
Log ₁₀ IP-10 week 1 ^d		1.90 (0.18)	2.14 (0.38)	0.001 ^c	1.37 (1.11, 1.82)	--
Log ₁₀ MIP1β week 1 ^d		1.09 (0.16)	1.24 (0.26)	0.005 ^c	1.37 (1.07, 1.82)	--
Log ₁₀ IP-10 week 2 ^d		1.88 (0.14)	2.11 (0.40)	0.002 ^c	1.34 (1.08, 1.79)	--
Log ₁₀ MIP1β week 2 ^d		1.10 (0.13)	1.26 (0.27)	0.001 ^c	1.40 (1.10, 1.86)	1.42 (1.07, 2.00) *
Δ Log ₁₀ IL-18 w1-2 ^d		-0.02 (0.12)	0.02 (0.08)	0.16 ^c	1.47 (0.86, 2.72)	--

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^a Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^b P-values calculated by Fisher Exact Test

^c P-values calculated by independent sample *t* tests

^d Odds ratios were calculated per 0.1 unit increase

* p ≤ 0.05; ** p <0.01; *** p <0.001; calculated in final multivariable model

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Number and (Percentage) noted for all categorical variables

Supplementary Table 5. Correlates of SVR in patients with GT3 infection and cirrhosis who previously failed IFN therapy

	Relapse	SVR	P-value	OR (95% CI) ^a		
				Unadjusted	Adjusted	
Treatment Duration (wks)	12 16	6 (22.2%) 3 (11.1%)	5 (18.5%) 13 (48.1%)	0.10 ^b	1 [Reference] 5.20 (0.99, 33.5)	1 [Reference] 37.8 (1.38, 10,853) *
Log ₁₀ HCV RNA baseline ^e		5.32 (0.94)	6.43 (0.67)	0.01 ^c	1.18 (1.06, 1.36)	4.96 (1.04, 52.7) *
Log ₁₀ MCP1 baseline ^d		1.65 (0.12)	1.56 (0.15)	0.10 ^c	0.56 (0.24, 1.06)	0.16 (0.008, 0.65) **
Log ₁₀ MIP1β week 1 ^d		1.15 (0.17)	1.28 (0.22)	0.15 ^c	1.45 (0.92, 2.72)	2.38 (1.11, 8.46) *
Log ₁₀ MCP1 week 2 ^d		1.57 (0.15)	1.46 (0.16)	0.11 ^c	0.63 (0.32, 1.08)	--

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^a Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^b P-values calculated by Fisher Exact Test

^c P-values calculated by independent sample *t* tests

^d Odds ratios were calculated per 0.1 unit increase

^e Odds ratio was calculated per 1 log₁₀ increase in viral load

* p ≤ 0.05; ** p <0.01; *** p <0.001; calculated in final multivariable model

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Number and (Percentage) noted for all categorical variables

Supplementary Table 6. Correlates of SVR in all patients who failed IFN therapy regardless of HCV genotype and liver histology

	Relapse	SVR	P-value	OR (95% CI) ^a		
				Unadjusted	Adjusted	
Treatment Duration (wks)	12 16	11 (26.8%) 5 (12.2%)	11 (26.8%) 14 (34.1%)	0.20 ^b	1 [Reference] 2.80 (0.77, 11.2)	--
Log ₁₀ HCV RNA baseline ^e		5.95 (1.15)	6.41 (0.77)	0.18 ^c	1.67 (0.86, 3.50)	--
Log ₁₀ MIP1β week 1 ^d		1.11 (0.22)	1.26 (0.20)	0.03 ^c	1.49 (1.05, 2.40)	1.49 (1.05, 2.40) *
Log ₁₀ MIP1β week 2 ^d		1.10 (0.16)	1.20 (0.22)	0.14 ^c	1.31 (0.93, 2.00)	--

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

^a Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

^b P-values calculated by Fisher Exact Test

^c P-values calculated by independent sample *t* tests

^d Odds ratios were calculated per 0.1 unit increase


^e Odds ratio was calculated per 1 log₁₀ increase in viral load

* p ≤ 0.05; ** p <0.01; *** p <0.001; calculated in final multivariable model

"--" indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables

Number and (Percentage) noted for all categorical variables

A**B**